Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X:
“How do you defend a ‘no’ to access for patients desperately seeking treatment, when the package insert affirms the mechanism that Anktiva activates T cells and NK cells?
Peter Pitts provides the amazing truthful response that there is no reason. He highlights the mechanism of action in the package insert already approved. Peter also provides insight into the inconsistencies at the FDA when dealing with large pharma regarding approval with single arm trials versus biotech companies with a mission to cure cancer.”
Other articles about FDA on OncoDaily,